Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Early clinical trials evaluating the efficacy of GLP-1 receptor agonists reported a slightly increased risk of acute pancreatitis with these medications versus placebo or conventional treatment
Who Can Receive Weight Loss Medications Generally, prescriptions for FDA-approved weight loss medications are targeted at adults with a BMI over 30, or 27 with an additional weight-related medical condition like high cholesterol or diabetes
News GPs have been told not to initiate any new patients on either semaglutide or dulaglutide, which will also only have limited availability
Communicate with your provider about any side effects so they can document them properly
Retatrutide benefits stem from its unique status as a "triple agonist." While popular drugs like Ozempic mimic one hormone (GLP-1) and Mounjaro mimics two (GLP-1 and GIP), Retatrutide introduces a third player: Glucagon
